Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miroslav Styblo

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|November 27, 2002
Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes--mechanistic insights and implications for further experimentsMichael R Easterling, Miroslav Styblo, Marina V Evans, et al.
Chemical Research in Toxicology|December 16, 2017
Dose and Diet - Sources of Arsenic Intake in Mouse in Utero Exposure ScenariosManuela Murko, Brittany Elek, Miroslav Styblo, et al.
Environmental and Molecular Mutagenesis|June 13, 2003
Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrationsKanae Mure, Ahmed N Uddin, Laura C Lopez, et al.
Chemical Research in Toxicology|March 18, 2004
Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferaseStephen B Waters, Vicenta Devesa, Luz Maria Del Razo, et al.
Toxicology and Applied Pharmacology|April 6, 2005
Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotypeJiaxin Li, Stephen B Waters, Zuzana Drobna, et al.
Archives of Toxicology|April 12, 2020
Exposure to inorganic arsenic and its methylated metabolites alters metabolomics profiles in INS-1 832/13 insulinoma cells and isolated pancreatic isletsYuan-Yuan Li, Christelle Douillet, Madelyn Huang, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2016
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumorsMartin J Edelman, Rena Lapidus, Josephine Feliciano, et al.
Toxicology and Applied Pharmacology|July 28, 2004
Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetesFelecia S Walton, Anne W Harmon, David S Paul, et al.
Toxicology and Applied Pharmacology|September 27, 2005
Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administrationMichael F Hughes, Vicenta Devesa, Blakely M Adair, et al.
Toxicology and Applied Pharmacology|October 5, 2010
Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated miceMichael F Hughes, Brenda C Edwards, Karen M Herbin-Davis, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Pharmacokinetics and Pharmacodynamics|November 27, 2002
Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes--mechanistic insights and implications for further experimentsMichael R Easterling, Miroslav Styblo, Marina V Evans, et al.
Chemical Research in Toxicology|December 16, 2017
Dose and Diet - Sources of Arsenic Intake in Mouse in Utero Exposure ScenariosManuela Murko, Brittany Elek, Miroslav Styblo, et al.
Environmental and Molecular Mutagenesis|June 13, 2003
Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrationsKanae Mure, Ahmed N Uddin, Laura C Lopez, et al.
Chemical Research in Toxicology|March 18, 2004
Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferaseStephen B Waters, Vicenta Devesa, Luz Maria Del Razo, et al.
Toxicology and Applied Pharmacology|April 6, 2005
Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotypeJiaxin Li, Stephen B Waters, Zuzana Drobna, et al.
Archives of Toxicology|April 12, 2020
Exposure to inorganic arsenic and its methylated metabolites alters metabolomics profiles in INS-1 832/13 insulinoma cells and isolated pancreatic isletsYuan-Yuan Li, Christelle Douillet, Madelyn Huang, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2016
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumorsMartin J Edelman, Rena Lapidus, Josephine Feliciano, et al.
Toxicology and Applied Pharmacology|July 28, 2004
Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetesFelecia S Walton, Anne W Harmon, David S Paul, et al.
Toxicology and Applied Pharmacology|September 27, 2005
Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administrationMichael F Hughes, Vicenta Devesa, Blakely M Adair, et al.
Toxicology and Applied Pharmacology|October 5, 2010
Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated miceMichael F Hughes, Brenda C Edwards, Karen M Herbin-Davis, et al.
Pageof 4